Literature DB >> 7733898

Mechanism of inhibition of Ca(2+)-ATPase by myotoxin a.

K J Baker1, J M East, A G Lee.   

Abstract

The peptide DCRQKWKCCKKGSG [myotoxin-(29-42)], corresponding to residues 29-42 of myotoxin a, inhibits the activity of the Ca(2+)-ATPase of skeletal muscle sarcoplasmic reticulum, with a Kd value of 19.4 microM at pH 7.5, in 100 mM KCl. The peptide YKQCHKKGGHCFPKEK, corresponding to residues 1-16 of myotoxin a, is a less potent inhibitor. Inhibition by myotoxin-(29-42) is reduced at low pH and at high ionic strength, suggesting that charge interactions are important in binding to the ATPase. Inhibition of the ATPase has been shown to follow from a decrease in the rate of dephosphorylation, with no effect on the rate of phosphorylation of the ATPase or on the rate of the Ca2+ transport step (E1PCa2-->E2P). Binding of myotoxin-(29-42) decreased the affinity of the ATPase for Ca2+ and Mg2+, and increased the rate of dissociation of the outer Ca2+ ion from the ATPase. Unlike the amphipathic peptide melittin, it is suggested that myotoxin-(29-42) does not bind significantly to the lipid bilayer portion of the sarcoplasmic reticulum. Fluorescence quenching studies suggest that it could bind to the ATPase in the vicinity of Cys-344 in the phosphorylation domain and Lys-515 in the nucleotide binding domain. Inhibition of the ATPase is observed when the ATPase is reconstituted in monomeric form in sealed vesicles, suggesting that aggregation of the ATPase is not involved in inhibition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7733898      PMCID: PMC1136686          DOI: 10.1042/bj3070571

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  49 in total

1.  Interaction of myotoxin a with the Ca2+-ATPase of skeletal muscle sarcoplasmic reticulum.

Authors:  P Volpe; E Damiani; A Maurer; A T Tu
Journal:  Arch Biochem Biophys       Date:  1986-04       Impact factor: 4.013

2.  The interaction of the ground and excited states of indole derivatives with electron scavengers.

Authors:  R F Steiner; E P Kirby
Journal:  J Phys Chem       Date:  1969-12

3.  Solid phase synthesis.

Authors:  B Merrifield
Journal:  Science       Date:  1986-04-18       Impact factor: 47.728

4.  Isolation of myotoxic component from rattlesnake (Crotalus viridis viridis) venom. Electron microscopic analysis of muscle damage.

Authors:  C L Ownby; D Cameron; A T Tu
Journal:  Am J Pathol       Date:  1976-10       Impact factor: 4.307

5.  Localization of the hinge region of the Ca(2+)-ATPase of sarcoplasmic reticulum using resonance energy transfer.

Authors:  K J Baker; J M East; A G Lee
Journal:  Biochim Biophys Acta       Date:  1994-06-01

6.  Effects of K+ on the binding of Ca2+ to the Ca(2+)-ATPase of sarcoplasmic reticulum.

Authors:  A G Lee; K Baker; Y M Khan; J M East
Journal:  Biochem J       Date:  1995-01-01       Impact factor: 3.857

7.  The hydrophilic domain of phospholamban inhibits the Ca2+ transport step of the Ca(2+)-ATPase.

Authors:  G Hughes; J M East; A G Lee
Journal:  Biochem J       Date:  1994-10-15       Impact factor: 3.857

8.  Mechanism of stimulation of the calcium adenosinetriphosphatase by jasmone.

Authors:  A P Starling; G Hughes; J M East; A G Lee
Journal:  Biochemistry       Date:  1994-03-15       Impact factor: 3.162

9.  Binding of Ca2+ to the (Ca(2+)-Mg2+)-ATPase of sarcoplasmic reticulum: equilibrium studies.

Authors:  I M Henderson; Y M Khan; J M East; A G Lee
Journal:  Biochem J       Date:  1994-02-01       Impact factor: 3.857

10.  Calcium-activated tension of skinned muscle fibers of the frog. Dependence on magnesium adenosine triphosphate concentration.

Authors:  R E Godt
Journal:  J Gen Physiol       Date:  1974-06       Impact factor: 4.086

View more
  1 in total

1.  An investigation of the mechanism of inhibition of the Ca(2+)-ATPase by phospholamban.

Authors:  G Hughes; A P Starling; R P Sharma; J M East; A G Lee
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.